Axovant Sciences (NASDAQ: AXON)   On Monday morning before the market opened, Axovant Sciences announced that they were ending their program that treated dementia when it failed to meet the primary endpoints in a phase 2 trial. This is devastating news for shareholders as share prices have shed over 45% and are now trading near […]